Ignite Creation Date:
2024-05-06 @ 4:28 PM
Last Modification Date:
2024-10-26 @ 2:10 PM
Study NCT ID:
NCT04992156
Status:
COMPLETED
Last Update Posted:
2022-05-19
First Post:
2021-08-01
Brief Title:
Prediction of 18F-FES-PETCT Parameters on Palbociclib Combined With ET
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
A Retrospective Study of Prediction of 18F-FES-PETCT Parameters on the Outcome of Palbociclib Combined With Endocrine Therapy in Patients With HR and HER2-metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate parameters based on 18F-FES-PETCT so as to estimate the outcome of palbociclib combined with endocrine therapy in patients with HRHER2-MBC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None